1. Home
  2. MDWD vs DDD Comparison

MDWD vs DDD Comparison

Compare MDWD & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • DDD
  • Stock Information
  • Founded
  • MDWD 2000
  • DDD 1986
  • Country
  • MDWD Israel
  • DDD United States
  • Employees
  • MDWD N/A
  • DDD N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • DDD Computer peripheral equipment
  • Sector
  • MDWD Health Care
  • DDD Technology
  • Exchange
  • MDWD Nasdaq
  • DDD Nasdaq
  • Market Cap
  • MDWD 208.2M
  • DDD 210.1M
  • IPO Year
  • MDWD 2014
  • DDD N/A
  • Fundamental
  • Price
  • MDWD $18.63
  • DDD $1.79
  • Analyst Decision
  • MDWD Strong Buy
  • DDD Hold
  • Analyst Count
  • MDWD 2
  • DDD 3
  • Target Price
  • MDWD $35.00
  • DDD $3.50
  • AVG Volume (30 Days)
  • MDWD 66.7K
  • DDD 3.0M
  • Earning Date
  • MDWD 08-14-2025
  • DDD 08-11-2025
  • Dividend Yield
  • MDWD N/A
  • DDD N/A
  • EPS Growth
  • MDWD N/A
  • DDD N/A
  • EPS
  • MDWD N/A
  • DDD N/A
  • Revenue
  • MDWD $19,213,000.00
  • DDD $431,756,000.00
  • Revenue This Year
  • MDWD $20.64
  • DDD N/A
  • Revenue Next Year
  • MDWD $25.71
  • DDD $3.55
  • P/E Ratio
  • MDWD N/A
  • DDD N/A
  • Revenue Growth
  • MDWD N/A
  • DDD N/A
  • 52 Week Low
  • MDWD $14.14
  • DDD $1.32
  • 52 Week High
  • MDWD $22.51
  • DDD $5.00
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 41.12
  • DDD 54.41
  • Support Level
  • MDWD $17.60
  • DDD $1.57
  • Resistance Level
  • MDWD $19.12
  • DDD $1.77
  • Average True Range (ATR)
  • MDWD 0.79
  • DDD 0.11
  • MACD
  • MDWD -0.15
  • DDD -0.00
  • Stochastic Oscillator
  • MDWD 37.84
  • DDD 35.83

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About DDD 3D Systems Corporation

3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.

Share on Social Networks: